clinical trial · NCT05760300
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
Gilead Sciences·phase1·completed·n = 41
Chronic Hepatitis D InfectionBulevirtide (BLV)
brief summary
The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.
started
Mar 15, 2023
primary completion
Jul 18, 2024
completion
Jul 23, 2024
last updated
Sep 18, 2025
official title
A Phase 1 Open-Label, Parallel-Design, Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide in Participants With Normal and Impaired Renal Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol